Basic Information
| LncRNA/CircRNA Name | NLIPMT |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR, Microarray, Western blot, other |
| Sample | BRCA tissues and cell lines(d MDA-MB-231, SKBR3, MDA-MB-453, MCF7, BT474, and BT549) |
| Expression Pattern | down-regulated |
| Function Description | Ectopic expression of NLIPMT inhibited mammary cell proliferation, motility in vitro. Moreover, lnc-NLIPMT reduced the growth of implanted MDA-MB-231 cells in vivo. Mechanistically, glycogen synthase kinase 3? (GSK3?) was identified as an effector protein regulated by lnc-NLIPMT. Inhibition of GSK3? activity restored NLIPMT-induced inhibition of proliferation and motility in breast cancer cells. |
| Pubmed ID | 30417392 |
| Year | 2019 |
| Title | Overexpression of Novel lncRNA NLIPMT Inhibits Metastasis by Reducing Phosphorylated Glycogen Synthase Kinase 3? in Breast Cancer |
External Links
| Links for NLIPMT | GenBank HGNC NONCODE |
| Links for breast cancer | OMIM COSMIC |